Finding · criterion S4
Oral and nasal peptides: does the evidence match the product?
Evidence for a molecule does not automatically establish evidence for every product containing it. Match the exact formulation, route, strength and intended use before applying a study or an approval claim to an oral, sublingual or nasal offer.
Start with the product, not the ingredient headline
A swallowed tablet, a product held under the tongue, a nasal spray and an injection have different routes of administration. Even two products described as oral can differ in formulation and how they are intended to be used. Sharing an ingredient name is not enough to show that they deliver equivalent exposure or have the same clinical evidence.
This distinction does not mean that an oral medicine cannot work. It means that a seller needs evidence relevant to the particular product being discussed. A successful trial of one formulation cannot silently become a trial of every tablet, drop or spray with a similar name.
What generic approval actually requires
FDA explains that an approved generic must meet requirements involving the active ingredient, strength, dosage form, route of administration and bioequivalence. These are product-specific requirements. A marketing claim that two offers contain the same molecule is much narrower than a finding that an approved generic meets those requirements.
Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness and quality before marketing in the way it reviews approved drugs. Calling a compounded preparation an alternative does not establish generic approval or equivalence. The terms compounded, generic and FDA-approved should therefore remain distinct when comparing offers.
Read a study for the match it actually supports
Identify what participants received, how it was administered, who was enrolled, what outcome was measured and over what period. Then compare those details with the advertised product. A study of an injected preparation does not by itself demonstrate the same outcome for a nasal preparation. A laboratory experiment also does not establish a clinical outcome in people.
If the seller cites only an ingredient page, ask for the specific publication and the reason it applies to the offered formulation. If it cites an approved medicine, look for that exact product’s prescribing information. Do not assume that a trial’s result applies to a different route, formulation, population or treatment purpose.
Useful questions before comparing the price
Ask whether the offered product is an FDA-approved medicine or a compounded preparation, what dosage form and route are supplied, and which evidence supports claims about that exact formulation. A response that repeats the ingredient name leaves the central question unanswered. The prescribing clinician can explain the clinical reasoning for a proposed option.
Peptide Alliance records product names and approval disclosures separately. An identifiable molecule makes an offer easier to describe; it does not establish that every claim made for its delivery method is supported. A lower price or a route advertised as more convenient supplies no missing equivalence evidence.
Related standard: S4. Compounding disclosure. Evidence for individual companies appears in the seller ledger.
Related reading
Sources
Related findings
Does an NDC number mean a peptide product is FDA-approved?No. FDA explicitly states that assignment of an NDC number and inclusion in its directory do not establish product approval.
How many sellers say the compounded drug is not FDA-approved?Fewer than the headline rate suggests. S4 has the highest pass rate of any criterion because a large block of sellers passes it by selling no compounded drugs at all; among the sellers the disclosure actually applies to, a real minority omits it.
Which peptides do the telehealth services actually sell?GLP-1 drugs lead, and sermorelin and NAD+ follow close behind. Several services list molecules whose compounding nomination was withdrawn, and a handful of sites call a product FDA-approved when no approved version of it is what they sell.
Medical records and prescription transfers are different requestsReceiving a copy of a medical record does not transfer a prescription or authorize another refill. Identify the clinical record holder for the records request, and ask the pharmacies or prescriber separately about any prescription action.